Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis

被引:8
作者
Vidal, Laura [1 ,2 ]
Pando, Elizabeth [1 ,2 ,5 ]
Blanco, Laia [1 ]
Fabregat-Franco, Carles [3 ]
Castet, Florian [3 ]
Sierra, Alexandre [3 ]
Macarulla, Teresa [3 ]
Balsells, Joaquim [1 ]
Charco, Ramon
Vivancos, Ana [1 ,4 ]
机构
[1] Vall dHebron Univ Hosp, Dept HPB & Transplant Surg, Barcelona, Spain
[2] Univ Autonoma Barcelona, Barcelona, Spain
[3] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Gastrointestinal & Endocrine Tumour Unit, Barcelona, Spain
[4] Vall dHebron Inst Oncol VHIO, Canc Genom Lab, Barcelona, Spain
[5] Hosp Univ Vall dHebron, Dept Hepatopancreato Biliary & Transplant Surg, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
关键词
ctDNA; Resectable pancreatic adenocarcinoma; Liquid biopsy; Pancreatic surgery; Non -touch isolation technique; Meta; -analysis; CIRCULATING TUMOR DNA; TOUCH ISOLATION TECHNIQUE; RAS GENE-MUTATIONS; CELL-FREE DNA; DUCTAL ADENOCARCINOMA; PROGNOSTIC VALUE; COLON-CANCER; DISSEMINATION; SURVIVAL; SURGERY;
D O I
10.1016/j.ctrv.2023.102604
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: It has been hypothesised that manipulation during surgery releases tumoral components into circulation. We investigate the effect of surgery on plasma-borne DNA biomarkers and the oncological outcomes in resectable pancreatic ductal adenocarcinoma (PDAC). We also compare non-touch isolation techniques (NTIT) with standard techniques.Materials and methods: We performed a systematic review and a meta-analysis of studies analysing liquid biopsy as circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), and messenger RNA (mRNA) in resectable PDAC patients who underwent surgery and its association with overall survival (OS) and disease-free survival (DFS). Research in EMBASE, Web of Science and PubMed was performed. The ctDNA shift negative-to-positive (ctDNA - /+) or ctDNA shift positive-to-negative (ctDNA +/-) before and after surgery was evaluated.Results: Twelve studies comprising 413 patients were included. Shorter OS and DFS were identified in patients with positive ctDNA status before (HR = 2.28, p = 0.005 and HR = 2.16, p = 0.006) or after surgery (HR = 3.88, p < 0.0001 and HR = 3.81, p = 0.03), respectively. Surgical resection increased the rate of ctDNA +/-. There were no differences in OS or DFS in the ctDNA +/- group compared with ctDNA +/+ or ctDNA -/+. However, there was a trend to shorter OS in the ctDNA -/+ group (HR = 5.00, p = 0.09). No differences between NTIT and standard techniques on liquid biopsy status were found.Conclusion: Positive ctDNA in the perioperative period is associated with a worse prognosis. Surgical resection has a role in the negativisation of liquid biopsy status. More studies are needed to assess the potential of minimally invasive techniques on ctDNA dynamics.
引用
收藏
页数:10
相关论文
共 58 条
  • [1] American Cancer Society, 2023, Cancer Facts & Figures 2023
  • [2] Pancreatic cancer: yesterday, today and tomorrow
    Ansari, Daniel
    Tingstedt, Bobby
    Andersson, Bodil
    Holmquist, Fredrik
    Sturesson, Christian
    Williamsson, Caroline
    Sasor, Agata
    Borg, David
    Bauden, Monika
    Andersson, Roland
    [J]. FUTURE ONCOLOGY, 2016, 12 (16) : 1929 - 1946
  • [3] Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
    Bettegowda, Chetan
    Sausen, Mark
    Leary, Rebecca J.
    Kinde, Isaac
    Wang, Yuxuan
    Agrawal, Nishant
    Bartlett, Bjarne R.
    Wang, Hao
    Luber, Brandon
    Alani, Rhoda M.
    Antonarakis, Emmanuel S.
    Azad, Nilofer S.
    Bardelli, Alberto
    Brem, Henry
    Cameron, John L.
    Lee, Clarence C.
    Fecher, Leslie A.
    Gallia, Gary L.
    Gibbs, Peter
    Le, Dung
    Giuntoli, Robert L.
    Goggins, Michael
    Hogarty, Michael D.
    Holdhoff, Matthias
    Hong, Seung-Mo
    Jiao, Yuchen
    Juhl, Hartmut H.
    Kim, Jenny J.
    Siravegna, Giulia
    Laheru, Daniel A.
    Lauricella, Calogero
    Lim, Michael
    Lipson, Evan J.
    Marie, Suely Kazue Nagahashi
    Netto, George J.
    Oliner, Kelly S.
    Olivi, Alessandro
    Olsson, Louise
    Riggins, Gregory J.
    Sartore-Bianchi, Andrea
    Schmidt, Kerstin
    Shih, Ie-Ming
    Oba-Shinjo, Sueli Mieko
    Siena, Salvatore
    Theodorescu, Dan
    Tie, Jeanne
    Harkins, Timothy T.
    Veronese, Silvio
    Wang, Tian-Li
    Weingart, Jon D.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)
  • [4] Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis
    Bunduc, Stefania
    Gede, Noemi
    Vancsa, Szilard
    Lillik, Veronika
    Kiss, Szabolcs
    Dembrovszky, Fanni
    Eross, Balint
    Szakacs, Zsolt
    Gheorghe, Cristian
    Miko, Alexandra
    Hegyi, Peter
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 169
  • [5] Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?
    Cabel, L.
    Proudhon, C.
    Mariani, P.
    Tzanis, D.
    Beinse, G.
    Bieche, I.
    Pierga, J. -Y.
    Bidard, F. -C.
    [J]. EJSO, 2017, 43 (05): : 949 - 962
  • [6] European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer
    Carioli, G.
    Malvezzi, M.
    Bertuccio, P.
    Boffetta, P.
    Levi, F.
    La Vecchia, C.
    Negri, E.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (04) : 478 - 487
  • [7] Meta-analysis of radical resection rates and margin assessment in pancreatic cancer
    Chandrasegaram, M. D.
    Goldstein, D.
    Simes, J.
    Gebski, V.
    Kench, J. G.
    Gill, A. J.
    Samra, J. S.
    Merrett, N. D.
    Richardson, A. J.
    Barbour, A. P.
    [J]. BRITISH JOURNAL OF SURGERY, 2015, 102 (12) : 1459 - 1472
  • [8] Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis
    Chen, Linyan
    Zhang, Yi
    Cheng, Yuan
    Zhang, Dan
    Zhu, Sha
    Ma, Xuelei
    [J]. GENE, 2018, 679 : 328 - 334
  • [9] Cohen SA, 2023, J CLIN ONCOL, V41, P5
  • [10] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
    Conroy, T.
    Hammel, P.
    Hebbar, M.
    Ben Abdelghani, M.
    Wei, A. C.
    Raoul, J. -L.
    Chone, L.
    Francois, E.
    Artru, P.
    Biagi, J. J.
    Lecomte, T.
    Assenat, E.
    Faroux, R.
    Ychou, M.
    Volet, J.
    Sauvanet, A.
    Breysacher, G.
    Di Fiore, F.
    Cripps, C.
    Kavan, P.
    Texereau, P.
    Bouhier-Leporrier, K.
    Khemissa-Akouz, F.
    Legoux, J. -L.
    Juzyna, B.
    Gourgou, S.
    O'Callaghan, C. J.
    Jouffroy-Zeller, C.
    Rat, P.
    Malka, D.
    Castan, F.
    Bachet, J. -B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) : 2395 - 2406